Remdesivir didn’t reduce mortality among COVID-19 in WHO study: Report

/ / News

A clinical trial reportedly found that Gilead Sciences Inc.’s COVID-19 treatment remdesivir had no impact on survival in patients with the coronavirus, according to a report in the Financial Times. Remdesivir, an antiviral, has received emergency use authorization in the U.S. based on clinical-trial data that showed it can reduce recovery times in severely ill COVID-19 patients. It has not been proven to reduce death in COVID-19 patients. The trial, which is being conducted by the World Health Organization, found that four drugs – remdesivir, hydroxychloroquine, AbbVie’s HIV drug Kaletra, and interferon – did not produce different mortality rates or reduce the need for ventilation among roughly 11,000 hospitalized patients, according to an unpublished study viewed by the FT. So far this year, Gilead’s stock is down 3.1%, shares of AbbVie have fallen 3.7%, and the S&P 500 has rallied 8.0%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.